Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2010 by Lotus Pharmaceutical.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
Lotus Pharmaceutical
ClinicalTrials.gov Identifier:
NCT01245166
First received: November 19, 2010
Last updated: NA
Last verified: November 2010
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2011
  Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):